FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078429706> ?p ?o ?g. }

• W2078429706 endingPage "33" @default.
• W2078429706 startingPage "27" @default.
• W2078429706 abstract "Recombinant interleukin-2 (rIL-2) is widely used in patients with advanced cancer to enhance killer cell functions. However, the main drawback of rIL-2 therapy is the frequent development of oliguric acute renal failure (ARF), presumably due to a vascular leak syndrome. The aim of this study was to evaluate the effect of low-dose dopamine infusion on this form of ARF. Nine patients with metastatic renal cancer and previous unilateral nephrectomy were treated with a continuous intravenous infusion of rIL-2 (3 x 10(6) Cetus units/m2/d) for 5 days (study A). After 1 week, all the patients repeated the same cycle, but with the addition of a continuous intravenous infusion of dopamine (2 micrograms/min/kg body weight) that was started at the third day of treatment (study B). During study A, all patients showed a progressive (up to 34%) decrease of creatinine clearance. After rIL-2 withdrawal, these alterations persisted and were associated with a reduction in urinary output, sodium urinary excretion, and plasma protein. In study B, dopamine administration after renal function impairment (delta glomerular filtration rate = -44%) led to a prompt improvement of creatinine clearance. Creatinine clearance showed a further significant enhancement after the withdrawal of both drugs, reaching a value within the baseline range on the third day of follow-up. Similarly, the decline in urinary output and sodium excretion during rIL-2 was promptly counteracted by dopamine; in addition, after withdrawal of rIL-2 and dopamine, plasma protein levels were normalized. In conclusion, our data suggest that rIL-2-induced ARF in cancer patients is due to renal hypoperfusion mainly caused by a reduction in oncotic pressure.(ABSTRACT TRUNCATED AT 250 WORDS)" @default.
• W2078429706 created "2016-06-24" @default.
• W2078429706 creator A5008160422 @default.
• W2078429706 creator A5009196186 @default.
• W2078429706 creator A5028486533 @default.
• W2078429706 creator A5034405911 @default.
• W2078429706 creator A5042872767 @default.
• W2078429706 creator A5049600349 @default.
• W2078429706 creator A5051933262 @default.
• W2078429706 creator A5056398873 @default.
• W2078429706 creator A5080793108 @default.
• W2078429706 creator A5082076973 @default.
• W2078429706 creator A5083295311 @default.
• W2078429706 date "1995-07-01" @default.
• W2078429706 modified "2023-10-13" @default.
• W2078429706 title "Interleukin-2—Induced renal dysfunction in cancer patients is reversed by low-dose dopamine infusion" @default.
• W2078429706 cites W1529386421 @default.
• W2078429706 cites W1768088721 @default.
• W2078429706 cites W1858735933 @default.
• W2078429706 cites W1904436785 @default.
• W2078429706 cites W1915622915 @default.
• W2078429706 cites W1966196375 @default.
• W2078429706 cites W1975568557 @default.
• W2078429706 cites W1978350435 @default.
• W2078429706 cites W1985981664 @default.
• W2078429706 cites W1988671604 @default.
• W2078429706 cites W2019568747 @default.
• W2078429706 cites W2052321243 @default.
• W2078429706 cites W2062543983 @default.
• W2078429706 cites W2062973204 @default.
• W2078429706 cites W2068008235 @default.
• W2078429706 cites W2074527342 @default.
• W2078429706 cites W2095223184 @default.
• W2078429706 cites W2095942814 @default.
• W2078429706 cites W2108117103 @default.
• W2078429706 cites W2222964685 @default.
• W2078429706 cites W2285002277 @default.
• W2078429706 cites W2322553446 @default.
• W2078429706 cites W2326245275 @default.
• W2078429706 cites W2335919173 @default.
• W2078429706 cites W4213008084 @default.
• W2078429706 doi "https://doi.org/10.1016/0272-6386(95)90149-3" @default.
• W2078429706 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7611264" @default.
• W2078429706 hasPublicationYear "1995" @default.
• W2078429706 type Work @default.
• W2078429706 sameAs 2078429706 @default.
• W2078429706 citedByCount "25" @default.
• W2078429706 countsByYear W20784297062013 @default.
• W2078429706 countsByYear W20784297062014 @default.
• W2078429706 countsByYear W20784297062017 @default.
• W2078429706 countsByYear W20784297062018 @default.
• W2078429706 countsByYear W20784297062020 @default.
• W2078429706 crossrefType "journal-article" @default.
• W2078429706 hasAuthorship W2078429706A5008160422 @default.
• W2078429706 hasAuthorship W2078429706A5009196186 @default.
• W2078429706 hasAuthorship W2078429706A5028486533 @default.
• W2078429706 hasAuthorship W2078429706A5034405911 @default.
• W2078429706 hasAuthorship W2078429706A5042872767 @default.
• W2078429706 hasAuthorship W2078429706A5049600349 @default.
• W2078429706 hasAuthorship W2078429706A5051933262 @default.
• W2078429706 hasAuthorship W2078429706A5056398873 @default.
• W2078429706 hasAuthorship W2078429706A5080793108 @default.
• W2078429706 hasAuthorship W2078429706A5082076973 @default.
• W2078429706 hasAuthorship W2078429706A5083295311 @default.
• W2078429706 hasConcept C10146269 @default.
• W2078429706 hasConcept C121608353 @default.
• W2078429706 hasConcept C126322002 @default.
• W2078429706 hasConcept C126894567 @default.
• W2078429706 hasConcept C134018914 @default.
• W2078429706 hasConcept C159641895 @default.
• W2078429706 hasConcept C197934379 @default.
• W2078429706 hasConcept C2780091579 @default.
• W2078429706 hasConcept C2780227381 @default.
• W2078429706 hasConcept C2780306776 @default.
• W2078429706 hasConcept C2780343553 @default.
• W2078429706 hasConcept C513476851 @default.
• W2078429706 hasConcept C71924100 @default.
• W2078429706 hasConcept C77411442 @default.
• W2078429706 hasConceptScore W2078429706C10146269 @default.
• W2078429706 hasConceptScore W2078429706C121608353 @default.
• W2078429706 hasConceptScore W2078429706C126322002 @default.
• W2078429706 hasConceptScore W2078429706C126894567 @default.
• W2078429706 hasConceptScore W2078429706C134018914 @default.
• W2078429706 hasConceptScore W2078429706C159641895 @default.
• W2078429706 hasConceptScore W2078429706C197934379 @default.
• W2078429706 hasConceptScore W2078429706C2780091579 @default.
• W2078429706 hasConceptScore W2078429706C2780227381 @default.
• W2078429706 hasConceptScore W2078429706C2780306776 @default.
• W2078429706 hasConceptScore W2078429706C2780343553 @default.
• W2078429706 hasConceptScore W2078429706C513476851 @default.
• W2078429706 hasConceptScore W2078429706C71924100 @default.
• W2078429706 hasConceptScore W2078429706C77411442 @default.
• W2078429706 hasIssue "1" @default.
• W2078429706 hasLocation W20784297061 @default.
• W2078429706 hasLocation W20784297062 @default.
• W2078429706 hasOpenAccess W2078429706 @default.
• W2078429706 hasPrimaryLocation W20784297061 @default.
• W2078429706 hasRelatedWork W1918853894 @default.

• next